Pharmacogenomic data submissions to the FDA: clinical pharmacology case studies

Author： Ruañño Gualberto   Collins Jerry M   Dorner Andrew J   Wang Sue-Jane   Guerciolini Roberto   Huang Shiew-Mei  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.5, Iss.5, 2004-07, pp. : 513-517

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Pharmacogenomic data submissions to the FDA: clinical case studies

By Trepicchio William L   Williams Grant A   Essayan David   Hall Sue T   Harty Lea C   Shaw Peter M   Spear Brian B   Wang Sue Jane   Watson Mark L  

Pharmacogenomics, Vol. 5, Iss. 5, 2004-07 ,pp. : 519-524

Future Medicine

Access to resources Recommend Favorite

Pharmacogenomic data submissions to the FDA: non-clinical case studies

By Leighton John K   DeGeorge Joseph   Jacobson-Kram David   MacGregor James   Mendrick Donna   Worobec Alexandra  

Pharmacogenomics, Vol. 5, Iss. 5, 2004-07 ,pp. : 507-511

Future Medicine

Access to resources Recommend Favorite

Joint pharmacogenomic data submissions guidance released by the US FDA, European Commission and the European Medicines Agency

By  

Pharmacogenomics, Vol. 7, Iss. 5, 2006-07 ,pp. : 659-661

Future Medicine

Access to resources Recommend Favorite

Pharmacogenomic data: FDA voluntary and required submission guidance

By Salerno Ronald A   Lesko Lawrence J  

Pharmacogenomics, Vol. 5, Iss. 5, 2004-07 ,pp. : 503-505

Future Medicine

Access to resources Recommend Favorite

Transcriptional profiling of peripheral blood cells in clinical pharmacogenomic studies

By Burczynski Michael E   Dorner Andrew J  

Pharmacogenomics, Vol. 7, Iss. 2, 2006-03 ,pp. : 187-202

Future Medicine

Access to resources Recommend Favorite